NYU Langone Research Leads to Accelerated Approval of Bladder Cancer Immunotherapy Drug – Newswise (press release)
|
NYU Langone Research Leads to Accelerated Approval of Bladder Cancer Immunotherapy Drug
Newswise (press release) Clinical trial research led by Arjun V. Balar, MD, of NYU Langone’s Perlmutter Cancer Center, helped pave the way for the recent FDA approval of the immunotherapy drug atezolizumab as a first-line treatment for advanced bladder cancer. |
BLABBERMOUTH.NET |
POISON Drummer Raising Money To Support Immunotherapy at UC San Diego Health
BLABBERMOUTH.NET Drummer Rikki Rockett feels very lucky to be on tour with his band, POISON, this spring. A year ago, he didn’t know if he would survive tongue cancer. But after participating in an immunotherapy clinical trial at Moores Cancer Center at UC San Diego … |
|
Goodbye Glybera! The World’s First Gene Therapy will be Withdrawn
Labiotech.eu (blog) The excitement about the therapy was undercut when it became clear Glybera would be a commercial failure. In October, it will officially be dead. uniQure has announced that it will not go for the renewal of its marketing authorization for Glybera in … |
Xconomy |
UniQure to Yank Pioneering Gene Therapy From Market in Europe
Xconomy [Updated, 9:33 a.m. ET, see below] It took decades to get the first gene therapy in the Western world to market. And it will apparently take only five years since for that product, a treatment from UniQure for a rare metabolic disorder, to fizzle out … Biotech firm pulls pioneering gene therapy due to no demandReuters Goodbye Glybera! The World’s First Gene Therapy will be WithdrawnLabiotech.eu (blog) UniQure Says It Will Not Pursue EC Marketing Renewal for Glybera Gene TherapyGenetic Engineering & Biotechnology News (blog) Seeking Alpha –FiercePharma –GlobeNewswire (press release) all 10 news articles » |
|
Homology Medicines to Present at the Alliance for Regenerative Medicine’s Cell & Gene Therapy Investor Day
Yahoo Finance BEDFORD, Mass., April 20, 2017 /PRNewswire/ — Homology Medicines, Inc., a genetic medicines company translating proprietary gene editing and gene therapy technologies into novel treatments for patients, announced today that its Chief Executive Officer … |